Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
12.8M
-
Shares change
-
+166K
-
Total reported value, excl. options
-
$597M
-
Value change
-
+$18.4M
-
Put/Call ratio
-
0.3
-
Number of buys
-
66
-
Number of sells
-
-45
-
Price
-
$46.80
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q3 2017
137 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q3 2017.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.8M shares
of 27.8M outstanding shares and own 45.95% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.25M shares), Krensavage Asset Management, LLC (1.01M shares), FIRST MANHATTAN CO (947K shares), VANGUARD GROUP INC (838K shares), STATE STREET CORP (721K shares), Invesco Ltd. (703K shares), RENAISSANCE TECHNOLOGIES LLC (681K shares), DIMENSIONAL FUND ADVISORS LP (562K shares), FARALLON CAPITAL MANAGEMENT LLC (412K shares), and Stonepine Capital Management, LLC (390K shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.